Rosuvastatin- Hanmi Pharmaceuticals

Drug Profile

Rosuvastatin- Hanmi Pharmaceuticals

Alternative Names: HGP 0816

Latest Information Update: 05 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Antihyperlipidaemics; Fluorobenzenes; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Dyslipidaemias

Most Recent Events

  • 01 Oct 2016 Hanmi Pharmaceuticals completes phase I trial in Hyperlipidaemia (Combination therapy, In volunteers) in South Korea (NCT02941796)
  • 01 Jul 2016 Hanmi Pharmaceuticals initiates phase I trial in Hyperlipidaemia (Combination therapy, In volunteers) in South Korea (NCT02941796)
  • 01 Jun 2016 Hanmi Pharmaceutical completes a phase III trial in Dyslipidaemias (Combination therapy) in South Korea (NCT02899455)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top